At that time Sanofi was cruising towards an important FDA approval for its Dupixent (dupilumab) injection for the skin disease also known as atopic dermatitis. Noting the blockbuster potential for ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

Sanofi is already a major player in the ASD market with its big-selling IL-4 and IL-13 inhibitor Dupixent (dupilumab), and the company has previously highlighted amlitelimab as one of a dozen ...

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

When giving gluteal injections, it is safest to use the upper outer quadrant. The choice of site for injection must be based on good clinical judgment, using the best evidence available and ...

Nov. 27, 2024 — A recent trial finds an injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further ...

From pioneering early industrial gripper systems to mastering Metal Injection Moulding, Germany’s Zimmer Group is today a leader in advanced automation and manufacturing technologies. With operations ...

For example, a growing number of allergic patients (e.g., asthma, atopic dermatitis) are being treated with biologics that block the IL-4/IL-13 axis (e.g., dupilumab, an anti-IL-4Rα mAb) (82, 120).